Completed the construction of a GMP pilot plant in its Hwasun production plant in Jeollanam-do, Korea

在韩国全罗南道的Hwasun生产工厂完成了GMP试点工厂的建设

Plans to expand its domain from vaccine development to the field of rare disease treatments by proactively securing mRNA platforms

计划通过主动保护mRNA平台，将其领域从疫苗开发扩展到罕见病治疗领域

YONGIN, South Korea, Dec. 1, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company (CEO, Eun-Chul Huh), announced on November 30th that it has completed the construction mRNA (messenger ribonucleic acid) production facility in its own vaccine production plant in Hwasun, Jeollanam-do, Korea, and will soon start the operation..

韩国龙仁，2023年12月1日/PRNewswire/-GC Biopharma（006280.KS），一家韩国生物制药公司（首席执行官，Eun-Chul Huh），于11月30日宣布已完成构建mRNA（信使核糖核酸）生产设施位于韩国全罗兰道Hwasun自己的疫苗生产工厂，并将很快开始运营。。

The production facility is a GMP pilot plant that will support the company's strategy to internalize various mRNA-related technologies while continuously building up related capabilities.

生产设施是GMP试点工厂，将支持公司将各种mRNA相关技术内化的战略，同时不断建立相关能力。

The new facility offers an 'all-in-one' production capability that accommodates all phases of mRNA production. It can, therefore, significantly reduce the contamination risk of transfer and allows prompt production response. In addition, the pilot plant has a 'single-use' production facility that will reduce the cross-contamination risk and enable the production of multiple products at once..

新设施提供“一体化”生产能力，可适应mRNA生产的所有阶段。因此，它可以显着降低转移的污染风险，并允许及时的生产响应。此外，试点工厂还有一个“一次性”生产设施，可以降低交叉污染风险，同时生产多种产品。。

Taking the mRNA as one of its new drug development platforms, GC Biopharma has been putting efforts in this area by signing the lipid nanoparticle (LNP) development and option agreement with Acuitas Therapeutics last year and establishing a new mRNA-LNP platform this year. It is now actively making R&D efforts to advance into a clinical stage.

以mRNA为新药开发平台之一，GC Biopharma去年通过与Acuitas Therapeutics签署脂质纳米粒子（LNP）开发和选择协议，并于今年建立新的mRNA LNP平台，一直在该领域做出努力。它现在正在积极进行研发工作，以进入临床阶段。

Currently, this platform is being applied to develop treatment for SSADHD, one of the rare diseases, as well as mRNA influenza vaccine..

目前，该平台正被用于开发罕见疾病之一SSADHD的治疗方法，以及mRNA流感疫苗。。

Based on the technologies and capabilities it would accumulate in the new mRNA production facility by testing the effectiveness and safety of various vaccines and treatment candidates, the company is planning to produce drugs for clinical trials in the GMP pilot plant with a roadmap to move on to commercialization and further to CMO business..

基于通过测试各种疫苗和治疗候选药物的有效性和安全性，它将在新的mRNA生产设施中积累的技术和能力，该公司计划在GMP试验工厂生产用于临床试验的药物，并制定路线图。商业化并进一步进入CMO业务。。

Jae Uk Jeong, Head of R&D at GC Biopharma said, 'Construction of the new production facility was a part of our project to move ahead in securing the mRNA platform technology. We expect the facility to be widely used in various joint R&D and responses to any future pandemics.'

GC Biopharma研发负责人Jae Uk Jeong表示，“新生产设施的建设是我们项目的一部分，旨在确保mRNA平台技术的发展。我们预计该设施将广泛用于各种联合研发和应对任何未来的流行病

About GC Biopharma

关于GC生物制药

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century..

GC Biopharma（以前称为Green Cross Corporation）是一家生物制药公司，提供挽救生命和维持生命的蛋白质治疗和疫苗。GC Biopharma总部设在韩国龙仁，是全球领先的血浆蛋白和疫苗产品制造商之一，半个多世纪以来一直致力于优质医疗保健解决方案。。

This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties and other factors.

本新闻稿可能包含前瞻性声明中的生物制药，这些声明表达了GC Biopharma管理层目前的信念和期望。此类声明不代表GC Biopharma或其对未来绩效的管理的任何保证，并且涉及已知和未知的风险，不确定性和其他因素。

GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule..

除法律或证券交易所规则要求外，GC Biopharma不承担更新或修改本新闻稿中包含的任何前瞻性声明或其可能做出的任何其他前瞻性声明的义务。。

GC Biopharma Contacts (Media)Seunghyun Baek[email protected]Sohee Kim[email protected]Yelin Jun[email protected]

GC Biopharma联系人（媒体）Seunghyun Baek[电子邮件保护]Sohee Kim[电子邮件保护]Yelin Jun[电子邮件保护]

SOURCE GC Biopharma

来源GC生物制药